Ultrasound contrast agent developer Sonus Pharmaceuticals reported net income of $2.1 million in its second quarter, thanks to patent litigation and insurance settlements of $4.3 million, the company said. During the quarter (end-June 30), the Bothell, WA-based firm had revenues of just $45,000, compared with revenues of $350,000 reported for the same period in 1999. In the second quarter of 1999, Sonus posted a net loss of $3.1 million.
By AuntMinnie.com staff writersJuly 13, 2000
Related Reading
FDA accepts Sonus response to EchoGen action letter, May 24, 2000.
Sonus takes over EchoGen rights, April 5, 2000.
Sonus gets another FDA action letter, March 14, 2000.
Sonus revises contrast deal with Abbott, February 17, 2000.
Nycomed payment buoys Sonus results, January 31, 2000.
Copyright © 2000 AuntMinnie.com
